Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Kodiak Sciences Inc
KOD | US
3.67
USD0.05
1.38%
KOD | US
About Kodiak Sciences Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
3.67
Open
3.62
High
3.73
Low
3.46
Kodiak Sciences Inc. a clinical stage biopharmaceutical company researches develops and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301) an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD) as well as Phase III clinical study for the treatment of diabetic macular edema naïve macular edema due to retinal vein occlusion and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501 a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601 a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto California.
View LessKOD | US
Risk
59.3
Sharpe
1.08
Luna's Score
51/100
Recommendation
Hold
Luna says (KOD | US)
What's Working
Positive Momentum
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Value Stock (Price to Book < 3)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
62.5%1 month
59.3%3 months
72.8%6 months
74.2%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.89
Debt to equity
0.82
Debt to assets
0.44
Ent. to EBITDA
-0.12
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-192.78M
MarketCap
193.10M
MarketCap(USD)
193.10M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-71.50
Short ratio
9.18
Short perc.
4.76
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
1.21
Range1M
1.42
Range3M
1.46
Volumes: Market Activity
Rel. volume
2.18
Price X volume
1.60M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.12 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.89 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 72.75 | - | Par |
| Debt to Equity | 0.82 | -1.23 | Expensive |
| Debt to Assets | 0.44 | 0.25 | Expensive |
| Market Cap | 193.10M | - | Emerging |
